Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31002809,mean residence time,"The mean residence time of pilocarpine after topical eyelid application to the eyelid skin, conjunctiva, eyeball, and plasma were 14.9, 8.50, 6.29, and 8.11 h, respectively.",Pharmacokinetics and Tissue Distribution of Pilocarpine After Application to Eyelid Skin of Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002809/),h,14.9,1000,DB01085,Pilocarpine
,31002809,mean residence time,"The mean residence time of pilocarpine after topical eyelid application to the eyelid skin, conjunctiva, eyeball, and plasma were 14.9, 8.50, 6.29, and 8.11 h, respectively.",Pharmacokinetics and Tissue Distribution of Pilocarpine After Application to Eyelid Skin of Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002809/),h,8.50,1001,DB01085,Pilocarpine
,31002809,mean residence time,"The mean residence time of pilocarpine after topical eyelid application to the eyelid skin, conjunctiva, eyeball, and plasma were 14.9, 8.50, 6.29, and 8.11 h, respectively.",Pharmacokinetics and Tissue Distribution of Pilocarpine After Application to Eyelid Skin of Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002809/),h,6.29,1002,DB01085,Pilocarpine
,31002809,mean residence time,"The mean residence time of pilocarpine after topical eyelid application to the eyelid skin, conjunctiva, eyeball, and plasma were 14.9, 8.50, 6.29, and 8.11 h, respectively.",Pharmacokinetics and Tissue Distribution of Pilocarpine After Application to Eyelid Skin of Rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31002809/),h,8.11,1003,DB01085,Pilocarpine
,8600180,steady-state volume of distribution,"At doses between 0.5 and 3.5 mg, dose-independent pharmacokinetic parameters included a small steady-state volume of distribution (2.4 to 3.0 L/kg), a high plasma clearance (0.026 to 0.03 L/kg/min), and a mean residence time of approximately 100 min.",A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600180/),[l] / [kg],2.4 to 3.0,4377,DB01085,Pilocarpine
,8600180,plasma clearance,"At doses between 0.5 and 3.5 mg, dose-independent pharmacokinetic parameters included a small steady-state volume of distribution (2.4 to 3.0 L/kg), a high plasma clearance (0.026 to 0.03 L/kg/min), and a mean residence time of approximately 100 min.",A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600180/),[l] / [kg·min],0.026 to 0.03,4378,DB01085,Pilocarpine
,8600180,mean residence time,"At doses between 0.5 and 3.5 mg, dose-independent pharmacokinetic parameters included a small steady-state volume of distribution (2.4 to 3.0 L/kg), a high plasma clearance (0.026 to 0.03 L/kg/min), and a mean residence time of approximately 100 min.",A pharmacokinetic and pharmacodynamic study of intravenous pilocarpine in humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600180/),min,100,4379,DB01085,Pilocarpine
,34391852,zeta potential,"The optimal formulation (UFGs 6; composed of 600 mg Phosphatidylcholine (PC), 20 mg cholesterol, 0.1:1 weight molar ratio of EA: PC and 1 gm glycerol) possessed nanovesicles (441.70 ± 1.13 nm) that entrapped 69.33 ± 0.28 % of GCV, with zeta potential value of -37.00 ± 0.42 mV and deformability index value of 74.68 ± 0.71.",3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34391852/),mv,-,6612,DB01085,Pilocarpine
,34391852,zeta potential,"The optimal formulation (UFGs 6; composed of 600 mg Phosphatidylcholine (PC), 20 mg cholesterol, 0.1:1 weight molar ratio of EA: PC and 1 gm glycerol) possessed nanovesicles (441.70 ± 1.13 nm) that entrapped 69.33 ± 0.28 % of GCV, with zeta potential value of -37.00 ± 0.42 mV and deformability index value of 74.68 ± 0.71.",3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34391852/),mv,37.00,6613,DB01085,Pilocarpine
,34391852,deformability index,"The optimal formulation (UFGs 6; composed of 600 mg Phosphatidylcholine (PC), 20 mg cholesterol, 0.1:1 weight molar ratio of EA: PC and 1 gm glycerol) possessed nanovesicles (441.70 ± 1.13 nm) that entrapped 69.33 ± 0.28 % of GCV, with zeta potential value of -37.00 ± 0.42 mV and deformability index value of 74.68 ± 0.71.",3D printed ocusert laden with ultra-fluidic glycerosomes of ganciclovir for the management of ocular cytomegalovirus retinitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34391852/),,74.68,6614,DB01085,Pilocarpine
,7175718,overall clearance,Pharmacokinetic analysis via the two-compartment open model showed that bile duct ligation caused a decrease in overall clearance from approximately 61.94 to 28.71 ml/kg/min.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[ml] / [kg·min],61.94,15479,DB01085,Pilocarpine
,7175718,overall clearance,Pharmacokinetic analysis via the two-compartment open model showed that bile duct ligation caused a decrease in overall clearance from approximately 61.94 to 28.71 ml/kg/min.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[ml] / [kg·min],28.71,15480,DB01085,Pilocarpine
,7175718,apparent volume of distribution,The significant reduction in the apparent volume of distribution from 3.76 to 2.72 liter/kg could be the result of reduced binding sites.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[l] / [kg],3.76,15481,DB01085,Pilocarpine
,7175718,apparent volume of distribution,The significant reduction in the apparent volume of distribution from 3.76 to 2.72 liter/kg could be the result of reduced binding sites.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),[l] / [kg],2.72,15482,DB01085,Pilocarpine
,7175718,elimination half-life,There was also a significant increase in the elimination half-life of procainamide from 47.39 to 78.64 min in bile duct ligated rats.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),min,47.39,15483,DB01085,Pilocarpine
,7175718,elimination half-life,There was also a significant increase in the elimination half-life of procainamide from 47.39 to 78.64 min in bile duct ligated rats.,Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175718/),min,78.64,15484,DB01085,Pilocarpine
,8095536,steady-state levels,"The low and high steady-state levels of mexiletine in blood plasma were attained at 0.259 +/- 0.123 and 1.616 +/- 0.475 micrograms mL-1, respectively, within the first 1-2 h after drug administration.",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),[μg] / [ml],0.259,17326,DB01085,Pilocarpine
,8095536,steady-state levels,"The low and high steady-state levels of mexiletine in blood plasma were attained at 0.259 +/- 0.123 and 1.616 +/- 0.475 micrograms mL-1, respectively, within the first 1-2 h after drug administration.",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),[μg] / [ml],1.616,17327,DB01085,Pilocarpine
,8095536,saliva to plasma drug concentration ratios (S/P ratio,"In parotid saliva, the high steady-state produced greater saliva to plasma drug concentration ratios (S/P ratio, 0.475 +/- 0.160) than that (0.386 +/- 0.131) at the low steady-state (P < 0.05).",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.475,17328,DB01085,Pilocarpine
,8095536,saliva to plasma drug concentration ratios (S/P ratio,"In parotid saliva, the high steady-state produced greater saliva to plasma drug concentration ratios (S/P ratio, 0.475 +/- 0.160) than that (0.386 +/- 0.131) at the low steady-state (P < 0.05).",Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.386,17329,DB01085,Pilocarpine
,8095536,S/P ratio,The S/P ratio for mandibular saliva at the high (0.204 +/- 0.060) steady-state was also greater than that at the low (0.158 +/- 0.050) steady-state (P < 0.01).,Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.204,17330,DB01085,Pilocarpine
,8095536,S/P ratio,The S/P ratio for mandibular saliva at the high (0.204 +/- 0.060) steady-state was also greater than that at the low (0.158 +/- 0.050) steady-state (P < 0.01).,Dependency of salivary excretion of mexiletine on the plasma concentration in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8095536/),,0.158,17331,DB01085,Pilocarpine
,22150444,ED(50),"Thirty minutes after the induction of SE, the calculated rat ED(50) for SPD against convulsive SE in this model was 84 mg/kg.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],84,21547,DB01085,Pilocarpine
,22150444,ED(50),"SPD ED(50) values in guinea pigs were 67 and 92 mg/kg when administered at SE onset or 40 min after SE onset, respectively.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],67,21548,DB01085,Pilocarpine
,22150444,ED(50),"SPD ED(50) values in guinea pigs were 67 and 92 mg/kg when administered at SE onset or 40 min after SE onset, respectively.",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [kg],92,21549,DB01085,Pilocarpine
,22150444,plasma levels,"Assuming linear pharmacokinetics (PK), the PK-PD (pharmacodynamic) results (rats) suggests that effective SPD plasma levels ranged between 8 and 40 mg/L (20 min after the onset of soman-induced seizures) and 12-50 mg/L (40 min after the onset of soman-induced seizures).",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [l],8 and 40,21550,DB01085,Pilocarpine
,22150444,plasma levels,"Assuming linear pharmacokinetics (PK), the PK-PD (pharmacodynamic) results (rats) suggests that effective SPD plasma levels ranged between 8 and 40 mg/L (20 min after the onset of soman-induced seizures) and 12-50 mg/L (40 min after the onset of soman-induced seizures).",A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22150444/),[mg] / [l],12-50,21551,DB01085,Pilocarpine
,1409379,terminal elimination half-life,"Elimination was rapid and generally biphasic, with a terminal elimination half-life of approximately 1.3 hr.",Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409379/),h,1.3,46047,DB01085,Pilocarpine
,1409379,systemic clearance,The systemic clearance of pilocarpine was high (2.22 +/- 0.49 L/kg/hr) and its steady-state volume of distribution (2.30 +/- 0.64 L/kg) was comparable to that of many other basic drugs.,Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409379/),[l] / [h·kg],2.22,46048,DB01085,Pilocarpine
,1409379,steady-state volume of distribution,The systemic clearance of pilocarpine was high (2.22 +/- 0.49 L/kg/hr) and its steady-state volume of distribution (2.30 +/- 0.64 L/kg) was comparable to that of many other basic drugs.,Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1409379/),[l] / [kg],2.30,46049,DB01085,Pilocarpine
,22007526,K,"When CS-PN/SE was administered topically to rabbit eyes, the ocular clearance and the mean resident time (MRT) of pilocarpine nitrate were found to be dramatically improved (P < 0.05) compared with PN/SE and pilocarpine nitrate solution (PNs), since the K(CS-PN/SE) was declined to 0.006 4 +/- 0.000 3 min(-1) while MRT was prolonged up to 155.4 min.",[Chitosan-coated ophthalmic submicro emulsion for pilocarpine nitrate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007526/),[3] / [min],0.006 4,46852,DB01085,Pilocarpine
up,22007526,MRT,"When CS-PN/SE was administered topically to rabbit eyes, the ocular clearance and the mean resident time (MRT) of pilocarpine nitrate were found to be dramatically improved (P < 0.05) compared with PN/SE and pilocarpine nitrate solution (PNs), since the K(CS-PN/SE) was declined to 0.006 4 +/- 0.000 3 min(-1) while MRT was prolonged up to 155.4 min.",[Chitosan-coated ophthalmic submicro emulsion for pilocarpine nitrate]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007526/),min,155.4,46853,DB01085,Pilocarpine
,22007526,maximum miosis,"Pharmacodynamics results showed that the maximum miosis of CS-PN/SE was as high as 46.3%, while the miotic response lasted 480 min which is 255 min and 105 min longer than that of PNs and PN/SE, respectively.",[Chitosan-coated ophthalmic submicro emulsion for pilocarpine nitrate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22007526/),%,46.,46854,DB01085,Pilocarpine
,8222723,ED50,"The addition of cyclodextrins produced a significant left-shift in the dose response curve, with an ED50 of 64 micrograms and 19 micrograms for pilocarpine and pilocarpine/5% cyclodextrin solutions, respectively.",Beta-cyclodextrins enhance bioavailability of pilocarpine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222723/),μg,64,54281,DB01085,Pilocarpine
,8222723,ED50,"The addition of cyclodextrins produced a significant left-shift in the dose response curve, with an ED50 of 64 micrograms and 19 micrograms for pilocarpine and pilocarpine/5% cyclodextrin solutions, respectively.",Beta-cyclodextrins enhance bioavailability of pilocarpine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222723/),μg,19,54282,DB01085,Pilocarpine
,6654048,time delay for the peak response,"The time delay for the peak response was 16.l3-24.0 min, and the constant for apparent rate of elimination was 0.69-0.81 h-1.",Prolonged pulse-entry of pilocarpine with a soluble drug insert. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654048/),min,16.l3-24.0,68130,DB01085,Pilocarpine
,6654048,apparent rate of elimination,"The time delay for the peak response was 16.l3-24.0 min, and the constant for apparent rate of elimination was 0.69-0.81 h-1.",Prolonged pulse-entry of pilocarpine with a soluble drug insert. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654048/),1/[h],0.69-0.81,68131,DB01085,Pilocarpine
,20046711,entrapment,The entrapment and encapsulation of pilocarpine after process optimization was found to be 82.63% and 62.5% respectively.,Albumin microspheres as an ocular delivery system for pilocarpine nitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20046711/),%,82.63,89030,DB01085,Pilocarpine
,20046711,encapsulation,The entrapment and encapsulation of pilocarpine after process optimization was found to be 82.63% and 62.5% respectively.,Albumin microspheres as an ocular delivery system for pilocarpine nitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20046711/),%,62.5,89031,DB01085,Pilocarpine
,28399267,concentration,The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg).,Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399267/),,24.2,91446,DB01085,Pilocarpine
,28399267,concentration,The concentration of THC in the iris-ciliary bodies at the 60- and 120-minute time points (53 and 57.4 ng/50 mg) were significantly greater than that of THC-Val-HS (24.2 and 11.3 ng/50 mg).,Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28399267/),,11,91447,DB01085,Pilocarpine
,2448449,saliva to plasma concentration ratio (S/P ratio),The mean saliva to plasma concentration ratio (S/P ratio) was significantly higher in parotid (0.974 +/- 0.243) than in mandibular (0.284 +/- 0.119) saliva samples.,Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2448449/),,0.974,93026,DB01085,Pilocarpine
,2448449,saliva to plasma concentration ratio (S/P ratio),The mean saliva to plasma concentration ratio (S/P ratio) was significantly higher in parotid (0.974 +/- 0.243) than in mandibular (0.284 +/- 0.119) saliva samples.,Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2448449/),,0.284,93027,DB01085,Pilocarpine
,15112864,terminal half-life,The oral 14C-dose was rapidly and almost completely absorbed from the duodenum and small intestine within 30 min in the male rat and 14C concentrations in plasma declined biexponentially with a terminal half-life of about 9 h.,"Absorption, distribution and excretion of 14C-pilocarpine following oral administration to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15112864/),h,9,116960,DB01085,Pilocarpine
,15112864,Recoveries,Recoveries of 14C in mass balance (excretion) studies were in the range 96-100%.,"Absorption, distribution and excretion of 14C-pilocarpine following oral administration to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15112864/),%,96-100,116961,DB01085,Pilocarpine
,27218460,absolute bioavailabilities,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),%,76,139682,DB01085,Pilocarpine
,27218460,absolute bioavailabilities,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),%,96,139683,DB01085,Pilocarpine
,27218460,clearance,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),[l] / [h·kg],1.8-1.5,139684,DB01085,Pilocarpine
,27218460,half-life,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),[l] / [h·kg],1.8-1.5,139685,DB01085,Pilocarpine
,27218460,half-life,"The absolute bioavailabilities of SPD following i.p. and i.m. administrations were 76% (i.p.) and 96% (i.p.), and its clearance and half-life were 1.8-1.5 L h(-1) kg(-1) and 0.5-1.7 h, respectively.","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),h,0.5-1.7,139686,DB01085,Pilocarpine
,27218460,brain-to-plasma AUC ratios,"The SPD brain-to-plasma AUC ratios were 1.86 (i.v.), 2.31 (i.p.), and 0.77 (i.m.).","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),,1.86,139687,DB01085,Pilocarpine
,27218460,brain-to-plasma AUC ratios,"The SPD brain-to-plasma AUC ratios were 1.86 (i.v.), 2.31 (i.p.), and 0.77 (i.m.).","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),,2.31,139688,DB01085,Pilocarpine
,27218460,brain-to-plasma AUC ratios,"The SPD brain-to-plasma AUC ratios were 1.86 (i.v.), 2.31 (i.p.), and 0.77 (i.m.).","Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27218460/),,0.77,139689,DB01085,Pilocarpine
,25442425,effective dose (ED50 ),"Racemic EMC exhibited a potent activity in the soman-induced SE model when administered 5 and 20 min after seizure onset with median effective dose (ED50 ) values of 33 and 48 mg/kg, respectively. (2R)-IPC and (2S)-IPC exhibited ED50 values similar to those of racemic IPC in the mouse and rat MES and scMet models.",Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[mg] / [kg],33,140158,DB01085,Pilocarpine
,25442425,effective dose (ED50 ),"Racemic EMC exhibited a potent activity in the soman-induced SE model when administered 5 and 20 min after seizure onset with median effective dose (ED50 ) values of 33 and 48 mg/kg, respectively. (2R)-IPC and (2S)-IPC exhibited ED50 values similar to those of racemic IPC in the mouse and rat MES and scMet models.",Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[mg] / [kg],48,140159,DB01085,Pilocarpine
,25442425,ED50,Racemic IPC had an ED50 value of 107 mg/kg in the pilocarpine-induced SE model when given 30 min after seizure onset.,Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[mg] / [kg],107,140160,DB01085,Pilocarpine
,25442425,clearance,Racemic EMC and IPC and their enantiomers had similar clearance (3.8-5.5 L/h/kg) and short half-life (<1 h).,Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),[l] / [h·kg],3.8-5.5,140161,DB01085,Pilocarpine
<,25442425,half-life,Racemic EMC and IPC and their enantiomers had similar clearance (3.8-5.5 L/h/kg) and short half-life (<1 h).,Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25442425/),h,1,140162,DB01085,Pilocarpine
,20015615,ED(50),Riluzole (1-4mg/kg) administered intraperitoneally before pilocarpine dose-dependently protected rats against seizures with the anticonvulsant ED(50) value (50% effective anticonvulsant dose) of 1.8 (1.3-2.6)mg/kg.,Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],1.8,180133,DB01085,Pilocarpine
,20015615,50% effective anticonvulsant dose,Riluzole (1-4mg/kg) administered intraperitoneally before pilocarpine dose-dependently protected rats against seizures with the anticonvulsant ED(50) value (50% effective anticonvulsant dose) of 1.8 (1.3-2.6)mg/kg.,Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],1.8,180134,DB01085,Pilocarpine
,20015615,CD(50),"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],350.8,180135,DB01085,Pilocarpine
,20015615,CD(50),"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],246.4,180136,DB01085,Pilocarpine
,20015615,50% effective convulsant dose,"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],350.8,180137,DB01085,Pilocarpine
,20015615,50% effective convulsant dose,"Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg.",Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20015615/),[mg] / [kg],246.4,180138,DB01085,Pilocarpine
,27789373,absolute bioavailability,The absolute bioavailability of 5-HMT hydrogels was 20.7% showed in pharmacokinetic study.,"Design of hydrogels of 5-hydroxymethyl tolterodine and their studies on pharmacokinetics, pharmacodynamics and transdermal mechanism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789373/),%,20.7,189720,DB01085,Pilocarpine
,15059558,recovery rate,The average recovery rate of pilocarpine from aqueous humor was 98.2%.,[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),%,98.2,227393,DB01085,Pilocarpine
,15059558,minimum detectable concentration,The minimum detectable concentration was 0.025 micro g/ml.,[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),[μg] / [ml],0.025,227394,DB01085,Pilocarpine
,15059558,peak concentration,"The peak concentration and half-life of pilocarpine in aqueous humor were 4.46 micro g/ml at 10 min and 31.83 min, respectively, in the experimental group.",[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),[μg] / [ml],4.46,227395,DB01085,Pilocarpine
,15059558,peak concentration,"Whereas, the peak concentration and half-life of pilocarpine in aqueous humor were 2.25 micro g/ml at 20 min and 22.98 min, respectively, in the control group.",[Ocular pharmacokinetics of 0.5% pilocarpine with sodium hyaluronate in rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059558/),[μg] / [ml],2.25,227396,DB01085,Pilocarpine
,3139809,peak concentration,The aqueous humor concentration of M79175 versus time profile showed the peak concentration of 850 ng/ml at 20 min after instillation of pH 7.0 eye drop solution.,"Corneal permeability of aldose reductase inhibitor, M79175. In vivo study on pharmacokinetic aspect. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3139809/),[ng] / [ml],850,229261,DB01085,Pilocarpine
,23891744,steady-state speed,Tolterodine permeated at the steady-state speed of 770.19 μg cm(-2)h(-1) and its release coincided with Higuchi Equation.,"Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891744/),[μg] / [(cm)^2],770.19,245212,DB01085,Pilocarpine
,23891744,absolute bioavailability,The absolute bioavailability of tolterodine was 11.47%.,"Preparation, characterization and pharmacological evaluation of tolterodine hydrogels for the treatment of overactive bladder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23891744/),%,11.47,245213,DB01085,Pilocarpine
,2492705,initial half-time,"The TRH plasma profile in TRH-infused dogs exhibited two-compartment characteristics with an initial half-time of 10.4 +/- 5.4 (mean +/- SD) min, a terminal half-time of 69.4 +/- 24 min, and a metabolic clearance rate of 7.64 +/- 4.48 ml.min-1.kg-1.",TRH pharmacokinetics and nerve stimulation evoked prostatic fluid secretion during TRH infusion in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492705/),min,10.4,247066,DB01085,Pilocarpine
,2492705,terminal half-time,"The TRH plasma profile in TRH-infused dogs exhibited two-compartment characteristics with an initial half-time of 10.4 +/- 5.4 (mean +/- SD) min, a terminal half-time of 69.4 +/- 24 min, and a metabolic clearance rate of 7.64 +/- 4.48 ml.min-1.kg-1.",TRH pharmacokinetics and nerve stimulation evoked prostatic fluid secretion during TRH infusion in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492705/),min,69.4,247067,DB01085,Pilocarpine
,2492705,metabolic clearance rate,"The TRH plasma profile in TRH-infused dogs exhibited two-compartment characteristics with an initial half-time of 10.4 +/- 5.4 (mean +/- SD) min, a terminal half-time of 69.4 +/- 24 min, and a metabolic clearance rate of 7.64 +/- 4.48 ml.min-1.kg-1.",TRH pharmacokinetics and nerve stimulation evoked prostatic fluid secretion during TRH infusion in the dog. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492705/),[ml] / [kg·min],7.64,247068,DB01085,Pilocarpine
,8902195,K(m),"The reaction at 37 degrees C follows Michaelis-Menten kinetics (K(m) = 2.78 +/- 0.48 mmol/liter, Vmax = 79 +/- 13 nmol min-1 ml 1; n = 5) and produces pilocarpic acid as the only detectable product.",Serum pilocarpine esterase activity and response to oral pilocarpine. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902195/),[mM] / [l],2.78,250208,DB01085,Pilocarpine
,8902195,Vmax,"The reaction at 37 degrees C follows Michaelis-Menten kinetics (K(m) = 2.78 +/- 0.48 mmol/liter, Vmax = 79 +/- 13 nmol min-1 ml 1; n = 5) and produces pilocarpic acid as the only detectable product.",Serum pilocarpine esterase activity and response to oral pilocarpine. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902195/),[1·ml·nM] / [min],79,250209,DB01085,Pilocarpine
,8902195,distribution,The distribution was positively skewed and ranged from 4 to 132 nmol min-1 ml-1 with a mean value of 55 +/- 23 nmol min-1 ml 1.,Serum pilocarpine esterase activity and response to oral pilocarpine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8902195/),[1·ml·nM] / [min],55,250210,DB01085,Pilocarpine
